Targeting the platelet-derived growth factor signalling in cardiovascular disease

Clinical and Experimental Pharmacology and Physiology

Volumn 42, Issue 12, 2015, Pages 1221-1224

  Hu, Weining ^a   Huang, Yu ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cardiovascular disease; Platelet derived growth factor

Indexed keywords

PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR C; PLATELET DERIVED GROWTH FACTOR D; LIGAND;

ANGIOGENESIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; HUMAN; INFLAMMATORY DISEASE; NONHUMAN; PROTEIN TARGETING; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION; WOUND HEALING; ANIMAL; CARDIOVASCULAR DISEASES; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; LIGANDS; MOLECULAR TARGETED THERAPY; PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84954413311     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12478     Document Type: Article

References (38)

1. Hannink M, Donoghue DJ. Structure and function of platelet-derived growth factor (PDGF) and related proteins. Biochim. Biophys. Acta 1989; 989: 1-10.
2. Cao Y. Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis. Trends Molec. Med. 2013; 19: 460-73.
3. Iqbal N, Iqbal N. Imatinib: A breakthrough of targeted therapy in cancer. Chemotherapy Res. Prac. 2014; 2014: 357027.
4. Karvinen H, Rutanen J, Leppanen O et al. PDGF-C and -D and their receptors PDGFR-alpha and PDGFR-beta in atherosclerotic human arteries. Eur. J. Clin. Investig. 2009; 39: 320-7.
5. Raines EW. PDGF and cardiovascular disease. Cytokine Growth Factor Rev. 2004; 15: 237-54.
6. Rossi E, Casali B, Regolisti G et al. Increased plasma levels of platelet-derived growth factor (PDGF-BB + PDGF-AB) in patients with never-treated mild essential hypertension. American J. Hypertens. 1998; 11: 1239-43.
7. Li H, Fu X, Zhang L, Huang Q, Wu Z, Sun T. Research of PDGF-BB gel on the wound healing of diabetic rats and its pharmacodynamics. J. Surg. Res. 2008; 145: 41-8.
8. Cui K, Zhou X, Luo J et al. Dual gene transfer of bFGF and PDGF in a single plasmid for the treatment of myocardial infarction. Experim. Therapeut. Med. 2014; 7: 691-6.
9. Reigstad LJ, Varhaug JE, Lillehaug JR. Structural and functional specificities of PDGF-C and PDGF-D, the novel members of the platelet-derived growth factors family. FEBS J. 2005; 272: 5723-41.
10. Demoulin JB, Essaghir A. PDGF receptor signaling networks in normal and cancer cells. Cytokine Growth Factor Rev. 2014; 25: 273-83.
11. Misiakos EP, Kouraklis G, Agapitos E et al. Expression of PDGF-A, TGFb and VCAM-1 during the developmental stages of experimental atherosclerosis. Eur. Surg. Res. 2001; 33: 264-9.
12. Floege J, Hudkins KL, Davis CL, Schwartz SM, Alpers CE. Expression of PDGF alpha-receptor in renal arteriosclerosis and rejecting renal transplants. J. Am. Soc. Nephrol. 1998; 9: 211-23.
13. Lemstrom K, Sihvola R, Tikkanen J et al. PDGF receptor inhibition prevents cardiac allograft arteriosclerosis in cholesterol-fed rabbits. Transplantation Proc. 2001; 33: 318.
14. Guo J, Li L, Wu YJ et al. Inhibitory effects of Brazilin on the vascular smooth muscle cell proliferation and migration induced by PDGF-BB. Am. J. Chinese Med. 2013; 41: 1283-96.
15. Schermuly RT, Dony E, Ghofrani HA et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J. Clin. Investig. 2005; 115: 2811-21.
16. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Rev. Drug Discovery 2002; 1: 493-502.
17. Chang YT, Ringman UA, Osterholm C et al. Antenatal imatinib treatment reduces pulmonary vascular remodeling in a rat model of congenital diaphragmatic hernia. Am. J. Physiol. Lung Cell. Molec. Physiol. 2012; 302: L1159-66.
18. Hansmann G, Wagner RA, Schellong S et al. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation 2007; 115: 1275-84.
19. Guignabert C, Alvira CM, Alastalo TP et al. Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF receptor-beta-dependent pulmonary arterial muscularization. Am. J. Physiol. Lung Cell. Molec. Physiol. 2009; 297: L1082-90.
20. Fukuda N, Kishioka H, Satoh C et al. Role of long-form PDGF A-chain in the growth of vascular smooth muscle cells from spontaneously hypertensive rats. Am. J. Hypertens. 1997; 10: 1117-24.
21. Katayose D, Ohe M, Yamauchi K et al. Increased expression of PDGF A- and B-chain genes in rat lungs with hypoxic pulmonary hypertension. Am. J. Physiol. 1993; 264: L100-6.
22. Ten Freyhaus H, Berghausen EM, Janssen W et al. Genetic Ablation of PDGF-Dependent Signaling Pathways Abolishes Vascular Remodeling and Experimental Pulmonary Hypertension. Arterioscl. Thromb. Vasc. Biol. 2015; 35: 1236-45.
23. Barst RJ. PDGF signaling in pulmonary arterial hypertension. J. Clin. Investig. 2005; 115: 2691-4.
24. Li L, Xu M, Li X et al. Platelet-derived growth factor-B (PDGF-B) induced by hypoxia promotes the survival of pulmonary arterial endothelial cells through the PI3K/Akt/Stat3 pathway. Cellular Physiol. Biochem. 2015; 35: 441-51.
25. Antoniu SA. Targeting PDGF pathway in pulmonary arterial hypertension. Expert Opin. Therapeut. Targets 2012; 16: 1055-63.
26. Gasparyan AY, Ayvazyan L, Pretorius E, Kitas GD. Platelets in rheumatic diseases: Friend or foe? Curr. Pharmaceut. Design 2014; 20: 552-66.
27. Mannaioni PF, Di Bello MG, Masini E. Platelets and inflammation: Role of platelet-derived growth factor, adhesion molecules and histamine. Inflamm. Res. 1997; 46: 4-18.
28. Nair DG, Miller KG, Lourenssen SR, Blennerhassett MG. Inflammatory cytokines promote growth of intestinal smooth muscle cells by induced expression of PDGF-Rbeta. J. Cell. Molec. Med. 2014; 18: 444-54.
29. Rubin K, Tingstrom A, Hansson GK et al. Induction of B-type receptors for platelet-derived growth factor in vascular inflammation: Possible implications for development of vascular proliferative lesions. Lancet 1988; 1: 1353-6.
30. Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Douglas KM, Kitas GD. Platelet function in rheumatoid arthritis: Arthritic and cardiovascular implications. Rheumatol. Int. 2011; 31: 153-64.
31. Pierce GF, Brown D, Mustoe TA. Quantitative analysis of inflammatory cell influx, procollagen type I synthesis, and collagen cross-linking in incisional wounds: Influence of PDGF-BB and TGF-beta 1 therapy. J. Lab. Clin. Med. 1991; 117: 373-82.
32. Schneider L, Cammer M, Lehman J et al. Directional cell migration and chemotaxis in wound healing response to PDGF-AA are coordinated by the primary cilium in fibroblasts. Cellular Physiol. Biochem. 2010; 25: 279-92.
33. Kaltalioglu K, Coskun-Cevher S, Tugcu-Demiroz F, Celebi N. PDGF supplementation alters oxidative events in wound healing process: A time course study. Arch. Dermatol. Res. 2013; 305: 415-22.
34. Fang RC, Galiano RD. A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Biologics Targets Therapy 2008; 2: 1-12.
35. Dong A, Seidel C, Snell D et al. Antagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-A. Angiogenesis 2014; 17: 553-62.
36. Kawano M, Koshikawa T, Kanzaki T, Morisaki N, Saito Y, Yoshida S. Diabetes mellitus induces accelerated growth of aortic smooth muscle cells: Association with overexpression of PDGF beta-receptors. Eur. J. Clin. Investig. 1993; 23: 84-90.
37. Guillausseau PJ, Dupuy E, Bryckaert MC et al. Platelet-derived growth factor (PDGF) in type 1 diabetes mellitus. Eur. J. Clin. Investig. 1989; 19: 172-5.
38. Yeboah J, Sane DC, Crouse JR, Herrington DM, Bowden DW. Low plasma levels of FGF-2 and PDGF-BB are associated with cardiovascular events in type II diabetes mellitus (diabetes heart study). Dis. Markers 2007; 23: 173-8.